A Phase 2 interventional study of Inobrodib and Pomalidomide in Multiple Myeloma Refractory and Multiple Myeloma in Relapse, sponsored by CellCentric Ltd.. Recruiting at 31 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by CellCentric Ltd. · Phase 2, Interventional, and Treatment
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
This is a Phase II, open-label, multicenter study to evaluate the efficacy and safety of inobrodib in combination with pomalidomide and dexamethasone (InoPd) in patients with relapsed and refractory multiple myeloma (RRMM).
Patients must be 18 years or older and be refractory to least one proteosome inhibitor (PI), one anti-CD38 monoclonal antibody (mAb) and pomalidomide. Patients must also be previously treated with an approved bispecific T-cell engager [TCE].
Approximately 100 patients will be treated with 20 mg of inobrodib administered orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle. Pomalidomide and dexamethasone will be administered as per standard of care (SoC), i.e., with a starting dose of 4 mg orally once daily on Day 1 to 21 of each 28-day cycle for pomalidomide, and 40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle for dexamethasone. Study treatment should be continued until disease progression, initiation of new anticancer therapy, unacceptable toxicity or the patient meets any criteria for withdrawal from the study.
The primary objective is to assess the efficacy of InoPd in terms of objective response rate (ORR) based on International Myeloma Working Group (IMWG) criteria and assessed by Independent Review Committee (IRC).
CellCentric Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Inobrodib · Drug: Pomalidomide · Drug: Dexamethasone
20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
Also known as: CCS1477
4 mg orally once daily on Day 1 to 21 of each 28-day cycle
Also known as: Pomalyst, Imnovid
40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle
Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC)
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
ORR, defined as the percentage of patients with a confirmed PR or better, based on IMWG criteria assessed by Investigator
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Duration of Response (DoR), defined as the duration of overall response by investigator and IRC
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Time to Response (TTR), defined as time to confirmed PR or better, by investigator and IRC
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Very Good Partial Response (VGPR) or better rate, defined as the percentage of patients with a confirmed VGPR or better, based on IMWG criteria and assessed by investigator and IRC
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Complete Response (CR) or better rate, defined as the percentage of patients with a confirmed CR or better, based on IMWG criteria and assessed by investigator and IRC
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Progression Free Survival (PFS), defined as the time from enrolment until the earliest date of Progressive Disease (PD), or death due to any cause, and assessed by investigator and IRC
Time frame: Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months)
Overall Survival (OS), defined as the time from enrolment to the date of death due to any cause
Time frame: Assessed from enrollment to date of death from any cause, until the end of study (up to 48 months)
Incidence of treatment-emergent adverse events (TEAEs), vital signs and laboratory abnormalities
Time frame: Assessed from start of treatment until 28 days after end of treatment
Plan to share: No — The final clinical study report will be provided to the Investigators. The Sponsor will publicly disclose study results through posting on ClinicalTrials.gov and any other applicable public registries in accordance with local regulations.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CellCentric Ltd.